US2020354735A1PendingUtilityA1
Plants with increased seed size
Assignee: INST GENETICS & DEVELOPMENTAL BIOLOGY CASPriority: Feb 3, 2015Filed: Jul 6, 2020Published: Nov 12, 2020
Est. expiryFeb 3, 2035(~8.5 yrs left)· nominal 20-yr term from priority
Inventors:Yunhai Li
A01H 5/10C12N 15/8261C12N 15/8218C07K 14/415Y02A40/146
35
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to genetically modified plants with an altered seed phenotype, in particular increased seed size. The invention relates to a plant that does not produce a functional NGAL2 polypeptide or functional NGAL2 and NGAL3 polypeptides. NGAL2 and NGAL3 are members of the RAV family and comprise a B3 DNA-binding domain and a transcriptional repression motif.
Claims
exact text as granted — not AI-modified1 .- 16 . (canceled)
17 . A method for altering a plant phenotype comprising reducing or abolishing the expression of a nucleic acid sequence encoding a NGAL2 polypeptide or reducing or abolishing the activity of a NGAL2 polypeptide, or reducing or abolishing the expression of a nucleic acid sequences encoding a NGAL3 polypeptide, or reducing or abolishing the activity of a NGAL3 polypeptide, or reducing or abolishing the expression of nucleic acid sequences encoding NGAL2 and NGAL3 polypeptides or reducing or abolishing the activity of a NGAL2 and NGAL3 polypeptide, relative to a control plant.
18 .- 22 . (canceled)
23 . The method according to claim 17 , wherein the NGAL2 polypeptide comprises SEQ D NO: 3, a functional variant or homologue thereof.
24 . The method according to claim 17 , wherein the nucleic acid sequence encoding a NGAL2 polypeptide comprises SEQ ID NO: 1 or 2, a functional variant or homologue thereof.
25 . The method according to claim 24 wherein the functional variant or homologue comprises a nucleic acid sequence as shown in SEQ ID NO: 49-145.
26 . The method according to claim 17 , wherein the NGAL3 polypeptide comprises SEQ ID NO: 5, a functional variant or homologue thereof.
27 . The method according to claim 17 wherein the NGAL3 nucleic acid sequence encoding a NGAL3 polypeptide comprises SEQ ID NO: 4, a functional variant or homologue thereof.
28 . The method according to claim 27 wherein the functional variant or homologue comprises SEQ ID NOs:49-145.
29 .- 33 . (canceled)
34 . The method according to claim 17 , wherein said phenotype is characterised by increased seed size relative to a control plant.
35 .- 36 . (canceled)
37 . A vector comprising SEQ ID NO: 1, 2 or 3 or a functional variant or homolog thereof.
38 . (canceled)Join the waitlist — get patent alerts
Track US2020354735A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.